Nyrada Inc – Nyrada Commences Key Brain Injury Program Preclinical Study
Highlights:
•NYR-BI03 Good Laboratory Practice (GLP) safety testing studies have commenced and are expected to conclude in 2HCY2024.
•First in-human Phase I clinical trial of NYR-BI03 on track to commence in 4QCY2024.
•March 2024 capital raise fully subscribed with $1.755 million received (before costs).
•Well-funded to conduct GLP studies and Phase I clinical trial of NYR-BI03.
ASX Announcement